These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 27371430)

  • 1. [A retrospective, observational and multicentre study on patients with hyperactive bladder on treatment with mirabegron and oxybutinine under usual clinical practice conditions].
    Sicras-Mainar A; Navarro-Artieda R; Ruiz-Torrejón A; Saez M; Coll-de Tuero G; Sánchez L
    Semergen; 2017; 43(4):277-288. PubMed ID: 27371430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice.
    Chapple CR; Nazir J; Hakimi Z; Bowditch S; Fatoye F; Guelfucci F; Khemiri A; Siddiqui E; Wagg A
    Eur Urol; 2017 Sep; 72(3):389-399. PubMed ID: 28196724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of persistence with mirabegron usage vs switching to onabotulinumtoxinA on healthcare costs and resource utilization in patients with overactive bladder in the United States.
    Ng DB; Espinosa R; Johnson SJ; Walker D; Gooch K
    J Med Econ; 2017 Dec; 20(12):1272-1280. PubMed ID: 28805473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, efficacy, and persistence of long-term mirabegron treatment for overactive bladder in the daily clinical setting: Interim (1-year) report from a Japanese post-marketing surveillance study.
    Kato D; Tabuchi H; Uno S
    Low Urin Tract Symptoms; 2019 Jan; 11(1):14-23. PubMed ID: 28762672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and persistence of low-dose mirabegron (25 mg) in patients with overactive bladder: analysis in a real-world urological practice.
    Shen YC; Wang HJ; Chuang YC
    Int Urol Nephrol; 2018 Jul; 50(7):1219-1226. PubMed ID: 29882001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and economic impact of mirabegron compared with antimuscarinics for the treatment of overactive bladder in Canada.
    Hakimi Z; Nazir J; McCrea C; Berling M; Fatoye F; Ramos B; Wagg A
    J Med Econ; 2017 Jun; 20(6):614-622. PubMed ID: 28286993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimated Budget Impact of Increased Use of Mirabegron, A Novel Treatment for Overactive Bladder.
    Perk S; Wielage RC; Campbell NL; Klein TM; Perkins A; Posta LM; Yuran T; Klein RW; Ng DB
    J Manag Care Spec Pharm; 2016 Sep; 22(9):1072-84. PubMed ID: 27579830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A retrospective study of treatment persistence and adherence to mirabegron versus antimuscarinics, for the treatment of overactive bladder in Spain.
    Nazir J; Hakimi Z; Guelfucci F; Khemiri A; Fatoye F; Blázquez AMM; González MH
    BMC Urol; 2018 Sep; 18(1):76. PubMed ID: 30180826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term Persistence with Mirabegron versus Solifenacin in Women with Overactive Bladder: Prospective, Randomized Trial.
    Kinjo M; Sekiguchi Y; Yoshimura Y; Nutahara K
    Low Urin Tract Symptoms; 2018 May; 10(2):148-152. PubMed ID: 27911988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in the United Kingdom.
    Nazir J; Maman K; Neine ME; Briquet B; Odeyemi IA; Hakimi Z; Garnham A; Aballéa S
    Value Health; 2015 Sep; 18(6):783-90. PubMed ID: 26409605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Overactive Bladder Step Therapy Policies on Medication Utilization and Expenditures Among Treated Medicare Members.
    Abbass IM; Caplan EO; Ng DB; Kristy R; Schermer CR; Bradt P; Collins JM; Chan WM; Suehs BT
    J Manag Care Spec Pharm; 2017 Jan; 23(1):27-37. PubMed ID: 28025920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resource use and healthcare costs in patients with overactive bladder who initiate treatment with mirabegron or antimuscarinic monotherapy in Catalonia: the MIRACAT study.
    Martins de Almeida R; Mateu Arrom L; Ortíz Núñez A; Covernton PJO; Mora Blazquez AM
    Actas Urol Esp (Engl Ed); 2022 Apr; 46(3):184-192. PubMed ID: 35305956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of treatment with mirabegron compared with solifenacin in the management of overactive bladder syndrome: A retrospective analysis.
    Schiavi MC; Faiano P; D'Oria O; Zullo MA; Muzii L; Benedetti Panici P
    J Obstet Gynaecol Res; 2018 Mar; 44(3):524-531. PubMed ID: 29271106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mirabegron for the treatment of overactive bladder: cost-effectiveness from US commercial health-plan and Medicare Advantage perspectives.
    Wielage RC; Perk S; Campbell NL; Klein TM; Posta LM; Yuran T; Klein RW; Ng DB
    J Med Econ; 2016 Dec; 19(12):1135-1143. PubMed ID: 27326725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and effectiveness of mirabegron in patients with overactive bladder aged ≥75 years: Analysis of a Japanese post-marketing study.
    Yoshida M; Nozawa Y; Kato D; Tabuchi H; Kuroishi K
    Low Urin Tract Symptoms; 2019 Jan; 11(1):30-38. PubMed ID: 28901041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urodynamic Efficacy and Safety of Mirabegron Add-on Treatment with Tamsulosin for Japanese Male Patients with Overactive Bladder.
    Wada N; Iuchi H; Kita M; Hashizume K; Matsumoto S; Kakizaki H
    Low Urin Tract Symptoms; 2016 Sep; 8(3):171-6. PubMed ID: 27619782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study).
    Yamaguchi O; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Okitsu A; Hamada T; Kobayashi A; Kuroishi K
    BJU Int; 2015 Oct; 116(4):612-22. PubMed ID: 25639296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Analysis of costs and consequences related to the persistence of Mirabegron and antimuscarinic treatments and their impact on quality of life in patients with overactive bladder in Spain: Results of a probabilistic model.].
    Arlandis Guzmán S; Jiménez Cidre MÁ; Rubio-Rodríguez D; Rubio-Terrés C; Landeira M; Blanco N
    Arch Esp Urol; 2020 Jul; 73(6):509-522. PubMed ID: 32633246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and Effectiveness of Mirabegron in Patients with Overactive Bladder in a Real-World Clinical Setting: A Japanese Post-Marketing Study.
    Nozawa Y; Kato D; Tabuchi H; Kuroishi K
    Low Urin Tract Symptoms; 2018 May; 10(2):122-130. PubMed ID: 27860325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug therapy for an overactive bladder.
    Thiagamoorthy G; Cardozo L; Srikrishna S
    Womens Health (Lond); 2015 Jul; 11(4):445-8. PubMed ID: 26238677
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.